Tryptamine Therapeutics ( (AU:TYP) ) has shared an announcement.
Tryptamine Therapeutics Limited announced the issuance of 162,000,000 unquoted equity securities, specifically options expiring on March 31, 2027, at an exercise price of $0.04. This strategic move is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s capital structure and providing additional resources for its ongoing projects.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative therapeutic solutions. The company is primarily engaged in creating products that address unmet medical needs, with a market focus on advancing novel treatments.
YTD Price Performance: -15.79%
Average Trading Volume: 1,658,752
Technical Sentiment Signal: Buy
Current Market Cap: A$40.85M
For a thorough assessment of TYP stock, go to TipRanks’ Stock Analysis page.